Screening for amblyopia risk factors in pre-verbal children using the Plusoptix photoscreener: a cross-sectional

Ali Akbar Saber Moghaddam1, Abbas Kargozar, Mehran Zarei-Ghanavati

  • 1Eye Research Center of the Mashhad University of Medical Sciences, Khatam-al-Anbia Eye Hospital, Mashhad, Iran.

Insights

The Plusoptix photoscreener shows promise for screening pre-verbal children for amblyopia risk factors, achieving high sensitivity but requiring further refinement for improved specificity in pediatric populations.

Area of Science:

  • Ophthalmology
  • Pediatric Optometry
  • Vision Screening Technology

Background:

  • Amblyopia, or "lazy eye," is a leading cause of vision impairment in children.
  • Early detection and intervention are crucial for effective amblyopia treatment.
  • Pre-verbal children present unique challenges for vision screening.

Purpose of the Study:

  • To assess the accuracy and practical use of the Plusoptix photoscreener for identifying amblyopia risk factors in very young children.
  • To compare Plusoptix measurements with cycloplegic retinoscopy findings.
  • To explore modifications to referral criteria to enhance the device's diagnostic performance.

Main Methods:

  • A cross-sectional study involving 996 children aged 6-36 months.
  • Screening using the Plusoptix photoscreener followed by comprehensive eye examinations, including cycloplegic retinoscopy.
  • Analysis of the prevalence of amblyogenic risk factors and comparison of Plusoptix data with retinoscopy results.

Main Results:

  • The Plusoptix demonstrated high testability (98.1%) and 100% sensitivity in detecting amblyogenic risk factors.
  • Initial referral criteria resulted in low specificity (38.7%).
  • Modified criteria (e.g., hyperopia ≥ 2.00 D in infants <12 months) improved specificity to 51.2% while maintaining high sensitivity.

Conclusions:

  • The Plusoptix serves as a valuable objective tool for pediatric vision screening.
  • Current specificity for detecting amblyopia risk factors in young children needs improvement.
  • Further research and optimized referral criteria are necessary to maximize the Plusoptix's clinical utility.
Abstract

Related Concept Videos